Tenofovir alafenamide is an antiretroviral developed by Gilead and the anti-HIV activity was reported in 1993. It is an investigational precursor to Tenovor, a nucleotide reverse transcriptase inhibitor. Tenofovir alafenamide is more efficient at delivering Tenofovir to target cells.
